EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

doi:10.1038/sj.onc.1209957

Back to search

Article

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

Oncogene - 8 Mar 2007

Choi S H, Mendrola J M, Lemmon M A

Abstract excerpt

Several somatic mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to gefitinib. To test the hypothesis that these mutations cause constitutive EGF receptor si...

Topics

Antineoplastic Agents
Cell Line, Tumor
Cell Membrane
Cell Proliferation
Epidermal Growth Factor
ErbB Receptors
Gefitinib
Humans
Interleukin-3
Lung Neoplasms
Models, Molecular
Mutation
Phosphorylation
Protein Binding
Quinazolines

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.